FilingReader Intelligence
GSK enters oncology with cancer therapies in India
August 25, 2025 at 05:39 AM UTC•By FilingReader AI
GSK launched Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its entry into oncology. Jemperli is India's first approved PD-1 immunotherapy for second-line dMMR/MSI-H advanced endometrial cancer, while Zejula is the sole once-daily oral PARP inhibitor for first-line maintenance in advanced ovarian cancer.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:GLAXO•Bombay Stock Exchange
News Alerts
Get instant email alerts when GlaxoSmithkline Pharmaceuticals publishes news
Free account required • Unsubscribe anytime